29 January 2018 | News
Angiex, a Biotech startup received funding From Agilent to improve angiogenesis research
Agilent Technologies Inc. has announced that biotech startup Angiex, Inc., has been awarded an Agilent Golden Ticket at LabCentral, providing funding of one lab bench space for a year.
Three semi-finalists presented their proposals at LabCentral’s Cambridge, Massachusetts, facility on Jan. 22, 2017.
The winner was chosen by a panel of judges consisting of Johannes Fruehauf, M.D., Ph.D., cofounder and president, LabCentral; Darlene Solomon, Ph.D., senior vice president and chief technology officer, Agilent; and John Gavenonis, vice president and general manager, Chemistries Division, Agilent CrossLab Group.
“All the semi-finalists in our Golden Ticket Event exhibited strong entrepreneurship, innovative scientific approaches, and great promise to advance healthcare. Angiex, our first-place winner, demonstrated an excellent combination of scientific impact, enthusiasm to collaborate with Agilent, and personal drive to advancing cancer treatments,” said Darlene Solomon, senior vice president and chief technology officer for Agilent.
Angiex was founded by world-class scientists to develop vascular-targeted biotherapeutics.
The main product of Angiex’s is an antibody-drug conjugate therapy for cancer.
Agilent as a platinum sponsor has equipped LabCentral's shared laboratory workspace with a variety of Agilent technology, including a high-resolution mass spectrometry system, and a cell analysis extracellular flux (XF) analyzer.
The sponsorship also includes a Golden Ticket which represents one year of bench space for a scientist, including benefit of LabCentral's shared infrastructure and services.